Take a look at our previous reports:

Annual Report 2022

Portfolio and outlook 2023

Portfolio

The following chart provides an overview of our lead product and product candidates currently in development as of the date of the publication of this report.

Portfolio (graphic)
Note: filgotinib is approved for RA and UC in Europe and Japan.
AxSpA, axial spondyloarthritis; RA, rheumatoid arthritis; UC, ulcerative colitis; rSLE, refractory systemic lupus erythematosus; DM, dermatomyositis; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma

Outlook 2023

Topline results

Filgotinib: FILOSOPHY Phase 4 in RA

GLPG5101:
CD19 CAR-T Phase 1 part of Phase 1/2 in NHL

GLPG5201:
CD19 CAR-T
Phase 1 part of
Phase 1/2 in CLL

Regulatory progress

CD19 CAR-T IND submission in the US

Trial initations

Filgotinib:
Phase 3 in AxSpA

CD19 CAR-T Phase 2 in rSLE

GLPG5101/
GLPG5201:
CD19 CAR-T NHL/CLL expansion cohorts

GLPG5301:
BCMA CAR-T Phase 1/2 in MM

GLPG3667:
TYK2i Phase 2 in DM & SLE

Outlook 2023 (graphic)
Development
All activities required to bring a new drug to the market. This includes preclinical and clinical development research, chemical and pharmaceutical development and regulatory filings of product candidates
Product candidate
Substance that has satisfied the requirements of early preclinical testing and has been selected for development, starting with formal preclinical safety evaluation followed by clinical testing for the treatment of a certain disorder in humans